Callan JMB Enters Agreement to Install Oral Drug Delivery Equipment in Texas Facility
Callan JMB (NASDAQ:CJMB) entered a preliminary agreement on November 13, 2025 to install an oral drug delivery manufacturer's production equipment at its cGMP facility in Spring Branch, Texas. The collaboration begins a phased effort to combine Callan JMB's cGMP warehousing, licensing, certification, and distribution capabilities with the client's manufacturing technology for fast-dissolving oral strips that offer an alternative to intravenous injections.
The companies are negotiating operational terms while Callan JMB positions this move as part of broader onshoring and manufacturing initiatives with global healthcare partners, including planned efforts with Revival Health.
Callan JMB (NASDAQ:CJMB) ha raggiunto un accordo preliminare il 13 novembre 2025 per installare l'impianto di produzione di un produttore di somministrazione orale presso la sua struttura cGMP a Spring Branch, in Texas. La collaborazione avvia un'azione a fasi per combinare le capacità di magazzinaggio cGMP, concessione di licenze, certificazioni e distribuzione di Callan JMB con la tecnologia di produzione del cliente per strisce orali a rapido scioglimento che offrono un'alternativa alle iniezioni endovenose.
Le aziende stanno negoziando i termini operativi mentre Callan JMB presenta questa mossa come parte di una più ampia strategia di reshoring e di iniziative di produzione con partner sanitari globali, includendo i futuri sforzi con Revival Health.
Callan JMB (NASDAQ:CJMB) acordó preliminarmente el 13 de noviembre de 2025 instalar el equipo de producción de un fabricante de administración oral en su instalación cGMP en Spring Branch, Texas. La colaboración da inicio a un esfuerzo por fases para combinar las capacidades de almacenamiento cGMP, licencias, certificaciones y distribución de Callan JMB con la tecnología de fabricación del cliente para tiras orales de disolución rápida que ofrecen una alternativa a las inyecciones intravenosas.
Las empresas están negociando los términos operativos mientras Callan JMB presenta este movimiento como parte de una iniciativa más amplia de reshoring y fabricación con socios globales de atención médica, incluyendo esfuerzos planificados con Revival Health.
Callan JMB (NASDAQ:CJMB)은 2025년 11월 13일에 예비 합의에 도달하여 텍사스 주 Spring Branch의 cGMP 시설에서 구강 투약 제제 제조업체의 생산 설비를 설치합니다. 협력은 Callan JMB의 cGMP 창고 관리, 허가, 인증 및 유통 역량을 고객의 제조 기술과 결합하여 빠르게 용해되는 경구 스트립에 대한 대안을 제공하는 정맥 주사에 대한 대안을 모색하는 다단계 노력을 시작합니다.
양사는 운영 조건을 협상 중이며 Callan JMB는 이 움직임을 글로벌 헬스케어 파트너들과의 온쇼어링 및 제조 이니셔티브의 일부로 제시하고 있으며 Revival Health와의 계획된 협력도 포함합니다.
Callan JMB (NASDAQ:CJMB) a conclu un accord préliminaire le 13 novembre 2025 pour installer l'équipement de production d'un fabricant de dispositifs d'administration orale dans son installation cGMP à Spring Branch, Texas. La collaboration lance un effort par étapes visant à combiner les capacités de stockage cGMP, de licences, de certifications et de distribution de Callan JMB avec la technologie de fabrication du client pour des bandes orales à dissolution rapide qui offrent une alternative aux injections intraveineuses.
Les entreprises négocient les termes opérationnels tandis que Callan JMB présente cette démarche comme faisant partie d'initiatives plus larges de relocalisation et de fabrication avec des partenaires mondiaux de la santé, y compris les efforts prévus avec Revival Health.
Callan JMB (NASDAQ:CJMB) hat am 13. November 2025 eine vorläufige Vereinbarung getroffen, um die Produktionsausrüstung eines Herstellers oraler Verabreichung in seine cGMP-Anlage in Spring Branch, Texas, zu installieren. Die Zusammenarbeit markiert den Beginn eines gestaffelten Vorhabens, die cGMP-Lagerung, Lizenzierung, Zertifizierung und Vertrieb von Callan JMB mit der Fertigungstechnologie des Kunden zu kombinieren, um schnelllösliche oralen Streifen zu entwickeln, die eine Alternative zu intravenösen Injektionen bieten.
Die Unternehmen verhandeln derzeit die betrieblichen Bedingungen, während Callan JMB diesen Schritt als Teil breiterer Onshoring- und Herstellungsinitiativen mit globalen Gesundheits-Partnern positioniert, einschließlich geplanter Bemühungen mit Revival Health.
Callan JMB (NASDAQ:CJMB) أبرمت اتفاقاً مبدئياً في 13 نوفمبر 2025 لتركيب معدات إنتاج لمُصنّع توصيل الدواء عن طريق الفم في منشأتهم cGMP في Spring Branch، تكساس. يبدأ التعاون جهدًا مرحليًا لدمج قدرات Callan JMB للخزن وفق cGMP، والتراخيص، والشهادات، والتوزيع مع تكنولوجيا التصنيع الخاصة بالعميل لشرائط فموية سريعة الذوبان تقدم بديلاً للحقن الوريدية.
تقوم الشركات بالتفاوض على الشروط التشغيلية بينما تُقدم Callan JMB هذه الخطوة كجزء من مبادرات إعادة التصنيع والتوطين الأوسع مع شركاء الرعاية الصحية العالميين، بما في ذلك الجهود المُخطط لها مع Revival Health.
- None.
- None.
Insights
Preliminary equipment-installation deal at Callan JMB's Texas cGMP site signals a move into manufacturing; outcome depends on final operational agreements.
Callan JMB will host an oral drug delivery manufacturer's equipment in its cGMP facility, combining the company's warehousing, licensing, certification, and distribution capabilities with the client's manufacturing technology for oral fast-dissolving strips. The arrangement targets onshoring of logistical and operational activities to the U.S. and expands Callan JMB's role from storage and distribution into processes involving Active Pharmaceutical Ingredients (APIs).
The announcement is explicit that the deal is preliminary and that the parties are still negotiating operational agreements, so commercial volume, timelines, and revenue are not disclosed. Successful execution depends on completing those operational contracts, installing and validating the equipment under cGMP rules, and any required certifications. Watch for the signed operational agreement, installation completion and validation, and any regulatory certifications; the press release date is
Agreement is the latest step in execution of the Company’s strategy to support onshoring of logistical and operational activities for international companies to the U.S.
SPRING BRANCH, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced that it has entered a preliminary agreement with the maker of an oral drug delivery system to install its innovative manufacturing equipment in Callan JMB’s cGMP facility in Texas, while the two companies negotiate operational agreements.
Callan JMB is entering the first phase of a collaboration combining Callan JMB’s capabilities in cGMP warehousing, licensing, certification, and drug distribution with the new client’s game-changing manufacturing equipment that creates oral fast-dissolving strips to provide an alternative to intravenous injections for numerous over-the-counter medicines.
“We are excited about this new partnership and the opportunities that installing the client’s manufacturing technology at our facility will open up for safe and effective oral drug delivery,” said Wayne Williams, CEO of Callan JMB. “This agreement is in line with our goals for expansion into ground-breaking healthcare and wellness technologies.”
Callan JMB sees the agreement as a fitting progression from its existing capacity for storage and distribution of finished medical products into the sourcing and use of Active Pharmaceutical Ingredients (“APIs”) in new manufacturing processes. This agreement is the latest step toward several related initiatives that are in the planning stages with global manufacturing leaders in the healthcare industry, such as Revival Health.
About Callan JMB
Callan JMB is an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services to secure medical materials and protect patients and communities with compliant, safe, and effective medicines. Our combined expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance and emergency preparedness is unparalleled in the industry. We offer the Gold Standard in client experience with customizable interfaces, next-level reliability in shipping and environmental sustainability in our specialty packaging.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge on the SEC's website at: http://www.sec.gov. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, and disclaims any intention or obligation to update or revise any such forward-looking statements to reflect events or circumstances that subsequently occur, or of which the Company hereafter becomes aware.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
CallanJMB@kcsa.com
212.896.1254
FAQ
What did Callan JMB (CJMB) announce on November 13, 2025 about its Texas facility?
How will the CJMB equipment installation affect Callan JMB's operations?
What product technology will be installed at Callan JMB (CJMB) in Texas?
Is the agreement between Callan JMB (CJMB) and the equipment maker final?
Does the CJMB announcement include financial terms or timelines for the Texas installation?
How does the Callan JMB (CJMB) deal relate to its onshoring strategy?
